Press Releases April 23, 2026 04:01 PM

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026

Kiniksa Pharmaceuticals to release Q1 2026 financial results and discuss recent portfolio developments on April 28, 2026

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
KNSA

Kiniksa Pharmaceuticals International announced it will report its first quarter 2026 financial results on April 28, 2026, via a conference call and webcast. The company will also discuss recent portfolio execution. The event will be accessible through the company's website, with a replay available shortly after.

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026
KNSA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Kiniksa Pharmaceuticals will announce Q1 2026 financial results on April 28, 2026.
  • The company will host a live webcast and conference call for investors and media.
  • Kiniksa focuses on developing novel therapies for diseases with unmet needs, particularly cardiovascular indications.

LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at 8:30 a.m. Eastern Time to report its first quarter 2026 financial results and recent portfolio execution.

A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.

Every Second Counts! ®

Kiniksa Investor & Media Contact
Jonathan Kirshenbaum
(781) 829-3949
jkirshenbaum@kiniksa.com


Risks

  • Financial results may not meet investor expectations, impacting stock price.
  • Pipeline therapies face typical biopharmaceutical development and commercialization risks.
  • Market competition and regulatory approvals could affect future growth and portfolio valuation.

More from Press Releases

Zhihu Inc. Announces Proposed Subscription in AI-Focused Investment Fund Sep 6, 2026 Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call Sep 6, 2026 Verizon Waives Charges for Hurricane Lowell, Prepares Network in Hawai'i Sep 5, 2026 Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen Sep 4, 2026 Grupo Aeroportuario del Pacifico Reports a Passenger Traffic Increase in August 2026 of 0.5% Compared to 2025 Sep 4, 2026